Lilly Hims deal puts Zepbound and Foundayo on telehealth at self pay prices

INDIANAPOLIS, Nov 6 (Peptide Zone) The Lilly Hims deal announced on Friday puts Eli Lilly's obesity medicines Zepbound and Foundayo on the Hims & Hers telehealth platform. Eligible patients who get a prescription from a licensed provider on the platform will pay the same self pay prices Lilly offers elsewhere, the companies said. The agreement comes eight months after Hims & Hers moved away from compounded weight loss drugs under legal pressure from Novo Nordisk. Financial terms were not disclosed.

What the Agreement Covers

The agreement covers two Lilly medicines. Zepbound, the brand name for tirzepatide, is a weekly injection approved to help adults with obesity, or overweight with weight related medical problems, lose weight and keep it off. It is also approved for moderate to severe obstructive sleep apnea in adults with obesity. Foundayo, the brand name for orforglipron, is a daily tablet that the FDA approved for weight management on April 1, 2026. Lilly describes it as a small molecule rather than a peptide. According to the joint press release, a patient completes a consultation on the platform and a licensed provider decides whether a prescription is appropriate. If it is, the medicine ships to the patient's home.

The release leaves several points open. It gives no financial terms, no start date for shipments and no target for patient numbers. It does not say how revenue is shared between the two companies. Lilly framed the agreement around access. Ilya Yuffa, president of Lilly USA, said in the release: "Millions of people turn to Hims & Hers for their care." He added that the agreement gives those patients "a simple, more direct way" to get Lilly medicine if prescribed. Hims & Hers chief executive Andrew Dudum called Lilly "one of the most innovative pharmaceutical companies in history." Both companies attached standard cautions that the agreement may not be carried out as planned or deliver its expected benefits.

Zepbound Self Pay Price and the Cash Market

Lilly said self pay pricing on the platform starts at $149 a month for Foundayo and $299 a month for Zepbound. BioPharma Dive reported that these match the self pay prices available through other channels. The Zepbound self pay price applies to patients paying out of pocket, so the agreement does not change what insurers cover. In practice, the deal does not lower what Lilly charges. It adds one more route to the same cash price. For Lilly, the value lies in reach. The company calls Hims & Hers one of the largest digital health platforms in the world. It also points to strong and growing interest among adults with obesity in getting care, including prescription medicines, through telehealth providers.

Lilly said self pay pricing on the platform starts at $149 a month for Foundayo and $299 a month for Zepbound.

The agreement lands as Lilly leans on volume. The company reported last month that volume growth outran price cuts in the third quarter. Foundayo has had a slower start than analysts expected, with third quarter Foundayo sales of $184 million falling short of forecasts, although Lilly said U.S. demand more than tripled. Platforms that prescribe telehealth obesity drugs give Lilly another route to patients who pay cash. Novo Nordisk signed its own agreement with Hims & Hers in March, so the two leading makers of GLP 1 obesity drugs now both have medicines on the same platform. Whether the new route changes Foundayo uptake will not be clear until later sales reports.

Compounded GLP 1 Past and the Novo Nordisk Lawsuit

Hims & Hers built much of its weight loss business on compounded GLP 1 drugs. These are copies made by compounding pharmacies, not the FDA approved branded products. BioPharma Dive reported that Hims had used legal loopholes to make lower cost compounded versions. On February 9, 2026, Novo Nordisk sued Hims & Hers in federal court in Delaware, according to a Hims & Hers quarterly filing. The Novo Nordisk lawsuit alleged patent infringement tied to compounded semaglutide offered through the platform and asked for an injunction. Novo dismissed the case without prejudice on March 9. That was the same day Hims & Hers announced an agreement with Novo to bring Ozempic and Wegovy to its platform.

In a March filing, Hims & Hers said it would stop advertising compounded GLP 1 offerings and would move existing patients to FDA approved medicines when providers judged that appropriate. It said it still planned to offer compounded drugs on a limited scale to patients whose providers find them clinically necessary. The new Lilly release adds a narrower pledge. Lilly said Hims & Hers has never offered compounded copies of Lilly's GLP 1 drugs and has committed not to do so in the future. The companies also said providers on the platform will keep independent clinical judgment over what they prescribe. Readers tracking compounding rules can find related reporting from our Safety desk.

What Is Not Yet Known About the Lilly Hims Deal

Several questions remain open. The companies did not say how many patients they expect to treat, how fast the drugs will appear on the platform, or how the money is split. They published no data on refill rates, side effect monitoring or patient outcomes on the platform. Lilly's release repeats the label warnings for both drugs, including possible thyroid tumors, pancreatitis, gallbladder problems and dehydration that can lead to kidney problems. Those warnings apply however a patient gets the medicine. The Lilly Hims deal also does not address people who still receive compounded semaglutide through other routes, and the release does not say whether such patients on the platform will be moved to Lilly drugs.

What comes next is mostly commercial. Lilly's next quarterly report may give a first hint of whether new channels lift Foundayo and Zepbound volume, although Lilly may not break out sales by platform. Hims & Hers will also report results that could show how many weight loss customers use branded drugs. In their forward looking statements, the companies flagged risks that include rollout timing, Hims & Hers' ability to meet its pricing and fulfillment commitments, and changes in how telehealth and pharmacy laws apply to prescription GLP 1 drugs. For now, the agreement is a distribution arrangement. It is not a price cut, it is not a new approval and it is not a clinical finding.

Conclusion

The Lilly Hims deal places Zepbound and Foundayo on a telehealth platform that once relied on compounded GLP 1 copies. Lilly said patients will pay the same self pay prices offered elsewhere, starting at $149 a month for Foundayo and $299 for Zepbound. Terms, timing and patient numbers were not disclosed. This story is research framing only and is not medical advice. Decisions about any prescription medicine belong with a licensed clinician.